There's a small but growing community trying to recast the story of longevity so it's digestible to the drug-making mainstream.
 Mike Reddy for STAT
No more 'playing God': How the longevity field is trying to recast its work as serious science Rather than a serious scientific field, longevity has been treated as a hybrid vice: An unholy graft of Icarian hubris and robber baron rapaciousness. There's a small but growing community trying to recast the story of longevity so it's digestible to the drug-making mainstream: Less cover of Time magazine, more portfolio of Pfizer. Read more. By Jason Mast |
|
 Molly Ferguson for STAT
They were the 10% left out of life-changing treatments. Now these cystic fibrosis patients may finally get help Revolutionary medications to treat cystic fibrosis don't work for some 10% of patients. Vertex and other companies are looking to scoop up these patients who feared being left behind. The fact that multiple companies are pursuing multiple approaches is a tantalizing sign to those patients that the progress they've been walled off from could start extending to them, even if for now the most advanced programs are still in early trials. Read more. By Andrew Joseph
 Adobe
These blood-clot catching devices have been controversial for years. Why are doctors still relying on them? Inferior vena cava filters are supposed to save lives. The spider-like devices catch blood clots before they can travel up to the lung and cause deadly pulmonary embolisms. But for over a decade, these devices have been dogged by questions about how well they work and the serious complications they can cause for patients. Read more. By Lizzy Lawrence
More great reads from STAT this week |
|
Check out more exclusive coverage with a STAT+ subscription | Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles. |
|
| STAT, 1 Exchange Place, Boston, MA | ©2023, All Rights Reserved. | |
|
No comments